The study, funded by the National Institute for Health and Care Research (NIHR), showed that active monitoring of low- and many intermediate-risk prostate cancers was safe and that death rates were essentially the same whether the men were assigned to surgery, or radiation, or were followed with what is now known as active surveillance.
ProtecT trial receives award for pioneering research demonstrating the safety of active surveillance
Press release issued: 13 August 2024
A study to find out the best ways of treating prostate cancer has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award. The ProtecT trial, led by the Universities of Bristol and Oxford, received the award for game-changing research in the development of the active surveillance approach to managing low-risk prostate cancer. Their research has proved active monitoring in patients with lower-risk prostate cancer was as safe as aggressive treatments.